OCEA — Ocean Biomedical Income Statement
0.000.00%
Last trade - 00:00- $0.14m
- $9.49m
Annual income statement for Ocean Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 62.3 | 16.1 | 25.3 | 3.8 |
| Operating Profit | -62.3 | -16.1 | -25.3 | -3.8 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -62.3 | -17.4 | -114 | -9.48 |
| Net Income After Taxes | -62.3 | -17.4 | -114 | -9.48 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -62.3 | -17.4 | -114 | -9.48 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -62.3 | -17.4 | -114 | -9.48 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1.83 | -0.51 | -3.78 | -0.345 |